Inveready leads a €12 million round in Nanoligent to advance the development of its cancer nanodrug — Inveready

Nanoligent, a biotechnology company specialized in the development of targeted nanodrugs for cancer treatment, has closed a €12 million funding round. The round was led by Inveready, through its Inveready Biotech IV fund, with additional participation from CDTI (via the Innvierte program), Clave Capital, through its Clave Innohealth fund, and current investors i&i Biotech Fund I, Italian Angels for Growth, and Avanteca.